Clinical Significance of KIAA1199 as a Novel Target for Gastric Cancer Drug Therapy
Clinical Significance of KIAA1199 as a Novel Target for Gastric Cancer Drug Therapy
复制标题
DOI：
10.21873/anticanres.13872
复制
发表时间：
2019-12
影响因子：
2
通讯作者：
Masataka Oneyama;N. Sakamoto;N. Oue;Y. Kimura;Yukihiko Hiroshima;I. Hashimoto;K. Hara;Y. Maezawa;K. Kano;T. Aoyama;H. Fujikawa;Takanobu Yamada;H. Tamagawa;N. Yamamoto;T. Ogata;Haruhiko Cho;H. Ito;N. Yukawa;M. Shiozawa;T. Yoshikawa;S. Morinaga;Y. Rino;M. Masuda;Y. Miyagi;W. Yasui;T. Oshima
中科院分区：
文献类型：
--
作者：
Masataka Oneyama;N. Sakamoto;N. Oue;Y. Kimura;Yukihiko Hiroshima;I. Hashimoto;K. Hara;Y. Maezawa;K. Kano;T. Aoyama;H. Fujikawa;Takanobu Yamada;H. Tamagawa;N. Yamamoto;T. Ogata;Haruhiko Cho;H. Ito;N. Yukawa;M. Shiozawa;T. Yoshikawa;S. Morinaga;Y. Rino;M. Masuda;Y. Miyagi;W. Yasui;T. Oshima
背景/目的：KIAA 1199基因与癌细胞增殖有关，但其功能研究仍然很少。在这里，我们研究了局部进展期胃癌（GC）中KIAA 1199 mRNA水平的临床意义。材料和方法/结果：使用来自254例II/III期GC患者的样本，我们发现癌组织中的KIAA 1199水平显著高于邻近正常粘膜（ANM）。KIAA 1199的表达与临床特征无明显关系。虽然接受手术的患者的总生存率（OSR）与KIAA 1199表达无关，但接受S-1辅助化疗且KIAA 1199水平较高的患者的OSR显著较低。KIAA 1199-KD抑制胃癌细胞的增殖、侵袭和对5-氟尿嘧啶（5-FU）的敏感性。结论：KIAA 1199表达似乎是局部晚期胃癌患者的一个有希望的预后标志物，这些患者接受了S-1的术后辅助化疗。KIAA 1199可能是GC药物治疗的新靶点。
Background/Aim: The KIAA1199 gene has been associated with cancer-cell proliferation, but its functions remain poorly studied. Here, we examined the clinical significance of the KIAA1199 mRNA levels in locally advanced gastric cancer (GC). Materials and Methods/Results: Using samples from 254 patients with stage II/III GC, we found significantly higher KIAA1199 levels in cancerous tissues compared to adjacent normal mucosa (ANM). There was no significant relationship between KIAA1199 expression and clinical features. Although overall survival rates (OSR) of patients, who underwent surgery did not correlate with KIAA1199 expression, patients who underwent adjuvant chemotherapy with S-1 and had high KIAA1199 levels displayed significantly lower OSR. KIAA1199 knock down (KIAA1199-KD) suppressed proliferation, invasiveness, and sensitivity of GC cells to 5-fluorouracil (5-FU). Conclusion: KIAA1199 expression appears to be a promising prognostic marker in patients with locally advanced GC, who underwent postoperative adjuvant chemotherapy with S-1. KIAA1199 may represent a novel target for GC pharmacotherapy.